Sensorion announces new positive clinical data from its gene therapy and small molecule programs at the World Congress of Audiology in Paris Page 1

Regulatory news:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore, treat and prevent hearing loss, today announced new positive medical data from its SENS-501 and SENS-401 clinical programs during a symposium (12:30-1:30 p.m. CET) and an oral presentation on SENS-401 (11:15 a.m. CET) held at the 36th Annual BioNTech Conference in Chicago.^th World Congress of Audiology (WCA), held in Paris at the CNIT, La Défense, France.

The company is reporting new data today from its pipeline of gene therapy (SENS-501) and small molecule programs (SENS-401). Details of these medical advances will be presented by professor
Natalie LoundonENT surgeon at the Necker-Enfants malades children’s hospital in Paris, France, professor Catherine Birman (ENT specialist, Director of the Sydney Cochlear Implant Centre, Australia), Professor Yann Nguyen (ENT surgeon, Pitié Salpétrière Hospital, Paris, France), Professor Stephen O’Leary (Head of Otorhinolaryngology, University of Melbourne, Australia) and professor Christophe Vincent (Head of Otology and Otoneurology, ENT surgeon, Salengro Hospital, Lille, France).